Aventis Divests Behring: CSL Enters Factor VIII Market In $925 Mil. Deal
Executive Summary
CSL will enter the U.S. Factor VIII market though its acquisition of Aventis Behring in a deal worth up to $925 mil
You may also be interested in...
Zemaira Convention Promotions Omit Risk Information, CBER Letter Says
ZLB Behring is requesting a meeting with CBER's advertising branch after receiving a warning letter citing Zemaira promotions used at a medical convention
Zemaira Convention Promotions Omit Risk Information, CBER Letter Says
ZLB Behring is requesting a meeting with CBER's advertising branch after receiving a warning letter citing Zemaira promotions used at a medical convention
Zemaira Clears FDA; Aventis Behring Seeks Distribution Partner
Aventis Behring is looking externally to boost the sales force for its Zemaira alpha-1 proteinase inhibitor